We have developed a proprietary and productive antibody discovery platform and have generated many monoclonal antibodies (patents filed on 11 sequenced antibodies): Our lead therapeutic antibody, a humanized IgG1, is Bstrazumab, and our lead therapeutic ADC is CM-14, Bstrazumab conjugated to the toxic payload MMAE. CM-14 is a first-in-class cancer ADC targeted for the therapeutic treatment for patients with advanced and metastatic solid-tumor cancers.

Mission Statement: Our mission is to generate therapeutic antibodies to novel cancer targets and
develop new cancer drugs to provide meaningful treatments and cures for patients with aggressive cancers.

CureMeta was founded in 2012 with the goal to discover novel targets and develop novel antibody therapeutic drugs to treat aggressive and metastatic cancers and provide real and meaningful benefits to patients suffering from these diseases.

Patent: We have filed patents on 11 antibodies that are specific to human cancers and not found in normal tissues. In 2019, we received a US patent on our lead therapeutic antibody, Bstrongximab, a therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.

Science: Almost all cancer deaths with solid tumor disease are caused by metastatic disease - the spread of cancer from its original location to distant areas within the body.  Once a primary tumor has spread, traditional treatments of surgery and radiation offer little hope for true recovery and quality of life. For many types of cancer, traditional chemotherapy is relatively ineffective, and death rates remain high for individuals with metastatic disease. In response to the problem CureMeta developed a unique antibody-drug development platform to generate highly specific and high-affinity monoclonal antibodies to embryonic protein and carbohydrate structures which are targets for aggressive and metastatic cancers.

The Cancer Problem: There are no good drugs for
treating metastatic cancer.
CureMeta’s Solution: New drugs to target and kill
the cancer stem cells responsible for tumor origin, progression, resistance, and metastasis

●  Metastatic cancer is the cause of death in over 90% of patients with solid tumors.
●  In just the US, over 63,000 patients with pancreatic or gastric cancer will die in 2024.
●  CureMeta’s drug development strategy is based on the premise that cancer is caused by malignant undifferentiated cancer cells with stem cell properties including embryonic stem cell properties.
●  CureMeta is developing new antibody-based drugs specific for embryonic cancer targets that are not found in normal tissue but present only on cancer stem cells in the tumor.

Next Steps: We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-14 into a human clinical cancer trial. During this next step, we will complete a human clinical phase 1 trial to generate safety and efficacy data in patients with these metastatic cancers. We anticipate minimal toxicity in the trial because the cancer target TRA-1-60 is not found in normal healthy tissues. Currently, there are no effective cancer treatments that offer any meaningful benefits or quality of life to patients suffering from these metastatic cancers. CM-14 has the potential to be a first-in-class humanized ADC to treat patients with pancreatic and gastric cancers.

We are developing a new Antibody and Antibody-Drug-Conjugate (ADC) therapeutic to treat and cure patients suffering from solid tumor and metastatic disease.